SAGE-547 in Super-Refractory Status Epilepticus
- Detailed data regarding effects of underlying disorders, and treatment approaches was presented from the open-label Phase 1/2 study of SAGE-547 in SRSE in a peer-reviewed setting for first time.
- Demonstrated that the 77% (17/22 in evaluable patients) key efficacy endpoint response rate (being successfully weaned off the anesthetic agents while SAGE-547 was being administered at the maintenance dose) was not related to age, gender, ethnicity, co-morbid medical condition, underlying medical condition, or previous antiepileptic or third line agent treatment.
- Subsequent post-hoc analysis involving duration of the weaning period (five days versus six days) showed that 16 of 22 (73%) evaluable subjects were successfully weaned off both anesthetic agents and SAGE-547 within five days of starting the SAGE-547 infusion without the need to reinstate anesthetic agents in the following 24-hour period, while 18 of 22 (82%) evaluable subjects were weaned off both anesthetic agents and SAGE-547 within six days of starting the SAGE-547 infusion without the need to reinstate anesthetic agents in the following 24-hour period, which is the key efficacy endpoint of the Phase 3 clinical trial.
- At baseline, patients were rated to be among the most extremely ill patients in the hospital, with ongoing status epilepticus averaging 9 days (range 3-20 days) before treatment.
- Overall, 64 percent of patients experienced at least one serious adverse event, though none were drug-related as determined by the Safety Review Committee. Individual serious adverse events reported in at least two patients were respiratory failure, pulmonary embolism, sepsis, convulsion and renal failure. Independent of treatment response, six patient deaths occurred within the study period, all driven by underlying medical conditions. The most common adverse events (reported in four or more patients) were fever, hypotension, diarrhea, peripheral edema, anemia and blood urea nitrogen (BUN) increase. One case each of fever and BUN increase were deemed related to SAGE-547 by the investigator.
- An exploratory pharmacodynamic biomarker was identified that was significantly correlated with the plasma concentration of SAGE-547 despite high baseline variability and presence of background medications.
- Sage is currently enrolling the STATUS Trial, a global Phase 3 randomized, double-blind, placebo-controlled clinical trial in SRSE with top-line results expected in the second half of 2016.
- Working closely with academic collaborators, Sage estimated the burden of illness of SRSE in the U.S. based on cases classified as SRSE using a treatment algorithm applied to a database of patient-level demographics, resource utilization (diagnostic and therapeutic services, diagnoses, procedures), and hospital data, for 2012.
- Mean length of stay (LoS), based on the cases classified in the study as SRSE using the primary algorithm, was 16.5 days with significant utilization of the ICU (mean LoS 9.3 days). LoS in the analysis ranged from 2 to over 800 days.
- SRSE has a high burden of illness with significant morbidity, lengthy hospitalizations and significant utilization of ICU and overall hospital resources.
- Significant reduction of tremor was observed in a randomized, double-blind, placebo-controlled, crossover trial of SAGE-547 in 25 patients with essential tremor.
- This proof-of-concept study using SAGE-547 was designed to evaluate the GABA mechanism as a potential treatment for essential tremor.
- This was a critical first step in developing assessment and statistical methodology for studying GABA-PAM (positive allosteric modulator) compounds in this indication.
- Of the 25 patients enrolled, three patients reported at least one adverse event on blinded SAGE-547, compared to five patients reporting at least one adverse event while on placebo. Of the 17 patients in the open-label, higher dose SAGE-547 portion, eight patients reported at least one adverse event. The only adverse events reported more than once across all SAGE-547 treatment periods were fatigue and dizziness, predominantly at the higher dose of SAGE-547. There was one discontinuation in the higher dose SAGE-547 portion due to hypotension, with recovery following drug discontinuation. There were no reports of serious adverse events.
- Sage intends to develop its next-generation GABA A modulator, SAGE-217, for essential tremor in a Phase 2 trial later this year, subject to successful completion of the ongoing Phase 1 clinical trials.
About Essential TremorEssential tremor is a common neurological condition that affects an estimated 10 million Americans and millions more worldwide. Essential tremor causes a rhythmic trembling of the hands, head, voice, legs or trunk. Symptoms generally evolve over time and are both visible and persistent following onset, which commonly occurs either between 15-20 or 50-70 years of age. First-line treatments for essential tremor include the anticonvulsant primidone and the ß-adrenergic blocker propranolol. Current treatments for essential tremor are only moderately effective, reducing, though not resolving, tremor amplitudes in about 50% of patients. In addition, one out of three patients abandons treatment due to side effects or poor efficacy. About Sage Therapeutics Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA and NMDA. Sage's lead program, SAGE-547, is in Phase 3 clinical development for super-refractory status epilepticus, a rare and severe seizure disorder. Sage is developing its next generation modulators, including SAGE-217, SAGE-689 and SAGE-718, with a focus on acute and chronic CNS disorders. For more information, please visit www.sagerx.com. Forward-Looking Statements Various statements in this release concerning Sage's future expectations, plans and prospects, including without limitation, our expectations regarding development of our product candidates and their potential in the treatment of various CNS disorders; the expected timing of clinical activities; the anticipated availability and announcement of data and results from clinical trials of our product candidates; and estimates of the potential number of patients and healthcare costs in the diseases for which we are developing our product candidates. These forward-looking statements are neither promises nor guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those contemplated in these forward-looking statements, including the risks that: we may experience slower than expected clinical site initiation, slower than expected identification and enrollment of evaluable patients, or the potential need for additional analysis or data or the need to enroll additional patients, leading to possible delays in completion of trials or in the availability of data; we may not be able to generate supportive non-clinical data or to successfully demonstrate the efficacy and safety of our product candidates at each stage of development; success in our non-clinical studies or in early stage clinical trials may not be repeated or observed in ongoing or future studies involving the same compound or other product candidates, and ongoing and future pre-clinical and clinical results may not support further development of product candidates or be sufficient to gain regulatory approval to market any product; decisions or actions of regulatory agencies may affect the initiation, timing, progress and cost of clinical trials, and our ability to proceed with further clinical studies of a product candidate or to obtain marketing approval; the actual size of the patient populations and healthcare costs associated with the diseases for which we are developing our product candidates may be significantly lower than our estimates; and we may encounter technical and other unexpected hurdles in the development and manufacture of our products, as well as those risks more fully discussed in the section entitled "Risk Factors" in our most recent Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent our views only as of today, and should not be relied upon as representing our views as of any subsequent date. We explicitly disclaim any obligation to update any forward-looking statements.